Dissemin is shutting down on January 1st, 2025

Published in

Portland Press, Biochemical Society Transactions, 4(39), p. 994-999, 2011

DOI: 10.1042/bst0390994

Links

Tools

Export citation

Search in Google Scholar

Deficient expression of bactericidal/permeability-increasing protein in immunocompromised hosts: Translational potential of replacement therapy

Journal article published in 2011 by Christine D. Palmer ORCID, Eva C. Guinan, Ofer Levy ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

BPI (bactericidal/permeability-increasing protein) is a 55 kDa anti-infective molecule expressed in neutrophil and eosinophil granules and on some epithelial cells. BPI's high affinity for the lipid A region of endotoxin targets its opsonizing, microbicidal and endotoxin-neutralizing activities towards Gram-negative bacteria. Several immunocompromised patient populations demonstrate BPI deficiency, including newborns, those with anti-neutrophil cytoplasmic antibodies (as in cystic fibrosis and HIV infection) and those exposed to radiochemotherapy. BPI may be replenished by administering agents that induce its expression or by administration of recombinant BPI congeners, potentially shielding BPI-deficient individuals against Gram-negative bacterial infection, endotoxemia and its toxic sequelae.